Medical Therapy. Adverse Effects or Lack of Adverse Effects

Efficacy and safety of treprostinil in pediatric pulmonary hypertension following fontan surgery: a real-world analysis

Mingjie Zhang, Xi Chen, Yahe Xu, Yijun Chen, Zhiyue Zhang, Jingru Zhou, Zhuoming XuShanghai Children’s Medical Center and Shanghai Jiao Tong University School of Medicine. China BioMedical Central PediatricsBMC Pediatr 2025; 25: DOI: 10.1186/s12887-025-06097-3 AbstractIntroduction: This study aimed to evaluate the efficacy and safety of treprostinil in managing pulmonary hypertension (PH) following Fontan surgery in children. The

Efficacy and safety of treprostinil in pediatric pulmonary hypertension following fontan surgery: a real-world analysis Read More »

Use of Dupilumab to Treat Cutaneous Complications of Continuous Prostacyclin Infusion in Pulmonary Hypertension: A Case Report and Review of Literature

Nidhy P. Varghese, Erin Ely, Rozmeen Fombin, Claire Champion, Elise WhalenBaylor College of Medicine and Texas Children’s Hospital.United States Pulmonary CirculationPulm Circ 2025; 15: DOI: 10.1002/pul2.70158 AbstractAdhesive reactions are common complications of continuous treprostinil infusions, limiting their recommended use as a treatment for severe pulmonary hypertension. We present the case of a 10-year-old male with recurrent

Use of Dupilumab to Treat Cutaneous Complications of Continuous Prostacyclin Infusion in Pulmonary Hypertension: A Case Report and Review of Literature Read More »

Nebulized Treprostinil in Mechanically Ventilated Children

Sarah P. Cohen, Diane Paulus, Ashley Hattie, Beth Malehorn, Mary Irmen, Robert GajarskiOhio State University and Nationwide Children’s Hospital. United States Pediatric PulmonologyPediatr Pulmonol 2025; 60: DOI: 10.1002/ppul.71278 AbstractAbstract Not Available CategoryMedical Therapy. Efficacy or Lack of EfficacyMedical Therapy. Adverse Effects or Lack of Adverse EffectsMedical Therapy. Pharmacokinetics and Pharmacology Age Focus: Pediatric Pulmonary Vascular Disease

Nebulized Treprostinil in Mechanically Ventilated Children Read More »

Nebulized nitroglycerin as an adjuvant drug in management of persistent pulmonary hypertension of newborns: a randomized controlled trial

Marwa Mohammed Farag, Hesham Abd El‑Rahim Ghazal, Aly Mohamed Abdel‑Mohsen, Moataz Ahmed RezkAlexandria University Hospital, Alexandria. Egypt European Journal of PediatricsEur J Pediatr 2025; 184: DOI: 10.1007/s00431-025-06381-5 AbstractThe objective was to evaluate the effect of nebulized nitroglycerin (NNG) in neonates with persistent pulmonary hypertension (PPHN). The study focused on assessing changes in echocardiographic and clinical parameters

Nebulized nitroglycerin as an adjuvant drug in management of persistent pulmonary hypertension of newborns: a randomized controlled trial Read More »

Case Report: Non-reactive vasoreactivity testing in a patient with patent ductus arteriosus with pulmonary hypertension: is there still a way to turn things around?

Sisca Natalia Siagian, Elsa Hedia Panjaitan, Pandu Prasetyo NugrohoUniversitas Indonesia.Indonesia Frontiers in Cardiovascular MedicineFront Cardiovasc Med 2025; 12: DOI: 10.3389/fcvm.2025.1569963 AbstractBackground: Recent guidelines recommend patent ductus arteriosus (PDA) closure in adults based on hemodynamic criteria, such as pulmonary vascular resistance (PVR) and flow ratio (Qp:Qs). However, additional parameters like acute vasoreactivity testing (AVT) and closure testing, though

Case Report: Non-reactive vasoreactivity testing in a patient with patent ductus arteriosus with pulmonary hypertension: is there still a way to turn things around? Read More »

Enhancing Drug Development for Paediatric Pulmonary Hypertension-An Integrative Perspective

Steven H. Abman, Sylvia M. Nikkho, Rolf M. F. Berger, Maria Jesus del Cerro, Eric D. Austin, Maurice Beghetti, Dunbar Ivy, Megan Griffiths, Anne Hilgendorff, Steven H. Kawut, Usha S. Krishnan, Mary P. Mullen, Shahin Moledina, Bernard Thébaud, Norman StockbridgeUniversity of Colorado School of Medicine and Children’s Hospital Colorado. Bayer AG. Beatrix Children’s Hospital, University

Enhancing Drug Development for Paediatric Pulmonary Hypertension-An Integrative Perspective Read More »

Stereotactic body radiotherapy: a new non-invasive way to conduct pulmonary artery denervation

Manzhen Liao, Taoyue Yao, Yonghui Xie, Shelby Kutty, Jinqiao Liu, Wei Peng, Ting Huang, Huaiyang Chen, Haoqin Fan, Zhenghui Xiao, Qiming Liu, Yunbin XiaoAffiliated Nanhua Hospital and University of South China. Affiliated Children’s Hospital of Xiangya School of Medicine and Central South University (Hunan Children’s Hospital). Johns Hopkins School of Medicine. China and Uhited States

Stereotactic body radiotherapy: a new non-invasive way to conduct pulmonary artery denervation Read More »

Cardiovascular protective properties of the natural product eugenol

Xin-yu Liu, Yun-ke Nie, Yang Liu, Mei ChenClinical College of Qilu Medical University. China European Journal of PharmacologyEur J Pharmacol 2025;DOI: 10.1016/j.ejphar.2025.177929 AbstractMedicinal herbs have long been used in traditional medicine and their multi-featured bioactivities against the pathophysiology of chronic diseases are currently being extensively investigated in both experimental and clinical settings. Eugenol, a versatile small

Cardiovascular protective properties of the natural product eugenol Read More »

Macitentan in Children with Pulmonary Arterial Hypertension: A Multicenter Experience

A. Rodriguez Ogando, A. Sabaté-Rotés, A. Moya Bonora, L. Albert de la Torre, J. M. Espín López, C. Labrandero de Lera, Maria Jesus Del Cerro MarinGregorio Marañon General University Hospital. Hospital Materno Infantil Gregorio Marañon. Vall d’Hebron University Hospital. La Fe University Hospital. 12 de Octubre University Hospital. Virgen dee la Arrixaca University Hospital. La

Macitentan in Children with Pulmonary Arterial Hypertension: A Multicenter Experience Read More »

Clinical Study to Evaluate the Possible Efficacy and Safety of L-Arginine in Children with Sickle Cell Disease and Increased Tricuspid Regurgitant Jet Velocity: a Randomized Controlled Trial

Dalia A. Gomaa, Sahar M. El‑Haggar, Mohamed R. El‑Shanshory, Osama El‑Razaky, Dalia R. El‑AffyTanta University. Egypt Paediatric DrugsPaediatr Drugs 2025; DOI: 10.1007/s40272-025-00701-w AbstractBackground: Pulmonary hypertension (PH) is a common chronic complication of sickle cell disease (SCD), and patients at risk for PH can be identified by measuring tricuspid regurgitant jet velocity (TRJV). We looked for the possible

Clinical Study to Evaluate the Possible Efficacy and Safety of L-Arginine in Children with Sickle Cell Disease and Increased Tricuspid Regurgitant Jet Velocity: a Randomized Controlled Trial Read More »

Scroll to Top